{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:40:19Z","timestamp":1792680019223,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":3524,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1093\/annonc\/mdq244","type":"journal-article","created":{"date-parts":[[2010,6,17]],"date-time":"2010-06-17T03:51:37Z","timestamp":1276746697000},"page":"v23-v30","source":"Crossref","is-referenced-by-count":154,"special_numbering":"S5","title":["Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"21","author":[{"given":"N.","family":"Colombo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Peiretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Parma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lapresa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mancari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Carinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq244_bb0010","series-title":"Cancer Facts and Figures 2008","author":"American Cancer Society","year":"2009"},{"key":"10.1093\/annonc\/mdq244_bb0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdq244_bb0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/annonc\/mdi098","article-title":"Cancer incidence and mortality in Europe 2004","volume":"16","author":"Boyle","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0025","first-page":"265","article-title":"Breast Cancer Linkage Consortium: breast and ovarian cancer incidence in BRCA1-mutation carriers","volume":"56","author":"Easton","year":"1995","journal-title":"Am J Hum Genet"},{"key":"10.1093\/annonc\/mdq244_bb0030","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","article-title":"Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program","volume":"94","author":"Brose","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdq244_bb0035","first-page":"496","article-title":"Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer","volume":"60","author":"Whittemore","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1093\/annonc\/mdq244_bb0040","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1200\/JCO.1998.16.7.2417","article-title":"Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk","volume":"16","author":"Frank","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0045","first-page":"650","article-title":"The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development","volume":"316","author":"The reduction in risk of ovarian cancer associated with oral-contraceptive use","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq244_bb0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJM200107263450401","article-title":"Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation","volume":"345","author":"Modan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq244_bb0055","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1001\/jama.1993.03510230051034","article-title":"Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study","volume":"270","author":"Hankinson","year":"1993","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdq244_bb0060","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq244_bb0065","first-page":"29","article-title":"Histopathologic grading of ovarian carcinoma: a review and a proposal","volume":"18","author":"Silverberg","year":"1999","journal-title":"Int J Gynecol Pathol"},{"key":"10.1093\/annonc\/mdq244_bb0070","first-page":"4","article-title":"Mucinous tumors of the ovary: a review","volume":"24","author":"Hart","year":"2005","journal-title":"Int J Gynecol Pathol"},{"key":"10.1093\/annonc\/mdq244_bb0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","article-title":"Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems","volume":"16","author":"Vang","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"10.1093\/annonc\/mdq244_bb0080","first-page":"161","article-title":"Histologic subtypes of ovarian carcinoma: an overview","volume":"27","author":"Soslow","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"10.1093\/annonc\/mdq244_bb0085","first-page":"151","article-title":"Pathogenesis of ovarian cancer: lesson from morphology and molecular biology and clinical implications","volume":"27","author":"Kurman","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"10.1093\/annonc\/mdq244_bb0090","first-page":"14","article-title":"Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer","volume":"80","author":"Einhorn","year":"1992","journal-title":"Obstet Gynecol"},{"key":"10.1093\/annonc\/mdq244_bb0095","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(09)70026-9","article-title":"Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)","volume":"10","author":"Menon","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2214\/AJR.09.3522","article-title":"MRI, CT, and PET\/CT for ovarian cancer detection and adnexal lesion characterization","volume":"194","author":"Iyer","year":"2010","journal-title":"Am J Roentgenol"},{"key":"10.1093\/annonc\/mdq244_bb0105","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1001\/jama.1983.03340220040030","article-title":"Staging laparotomy in early ovarian cancer","volume":"250","author":"Young","year":"1983","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdq244_bb0110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/gyno.2000.6027","article-title":"Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas","volume":"80","author":"Cass","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0115","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jnci\/dji102","article-title":"Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial","volume":"97","author":"Benedetti Panici","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdq244_bb0120","first-page":"568","article-title":"Misstaging of ovarian cancer","volume":"65","author":"McGowan","year":"1985","journal-title":"Obstet Gynecol"},{"key":"10.1093\/annonc\/mdq244_bb0125","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0130","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1200\/JCO.1986.4.7.1068","article-title":"Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma","volume":"4","author":"Wils","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0135","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0090-8258(91)90335-3","article-title":"Neoadjuvant chemotherapy and interval debulking surgery for advanced epithelial ovarian cancer","volume":"42","author":"Jacob","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0140","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.1987.5.8.1157","article-title":"Randomized trial comparing two combination chemotherapy regimens (CHAP5 vs. CP) in advanced ovarian carcinoma","volume":"5","author":"Neijt","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0145","first-page":"61","article-title":"Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced unresected epithelial ovarian cancer","volume":"73","author":"Lawton","year":"1989","journal-title":"Obstet Gynecol"},{"key":"10.1093\/annonc\/mdq244_bb0150","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM199503093321002","article-title":"The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer","volume":"332","author":"Van der Burg","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq244_bb0155","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2007.13.1953","article-title":"Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"26","author":"Winter","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0160","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1023\/A:1008424527668","article-title":"The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis","volume":"9","author":"Zanetta","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0165","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1471-0528.1997.tb12062.x","article-title":"Conservative surgery for stage I ovarian carcinoma in women of childbearing age","volume":"104","author":"Zanetta","year":"1997","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1093\/annonc\/mdq244_bb0170","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1995.1263","article-title":"Laparoscopic surgical staging of ovarian cancer","volume":"59","author":"Childers","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0175","first-page":"263","article-title":"Prognostic factors in patients with stage I epithelial ovarian cancer","volume":"75","author":"Dembo","year":"1990","journal-title":"Obstet Gynecol"},{"key":"10.1093\/annonc\/mdq244_bb0180","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/1097-0142(19900515)65:10<2349::AID-CNCR2820651031>3.0.CO;2-#","article-title":"Prognostic factors for survival in stage I epithelial ovarian carcinoma","volume":"65","author":"Sevelda","year":"1990","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq244_bb0185","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1525-1438.1994.04050333.x","article-title":"Different types of rupture of the tumor capsule and the impact on survival in early ovarian carcinoma","volume":"4","author":"Sjovall","year":"1994","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdq244_bb0190","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(00)03590-X","article-title":"Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma","volume":"357","author":"Vergote","year":"2001","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq244_bb0195","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/95.2.125","article-title":"International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with earlystage ovarian cancer","volume":"95","author":"Colombo","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdq244_bb0200","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1023\/A:1008399414923","article-title":"Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument","volume":"11","author":"Trope","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0205","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/oxfordjournals.annonc.a059355","article-title":"Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica","volume":"6","author":"Bolis","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004706.pub3","article-title":"Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer","author":"Winter-Roach","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdq244_bb0215","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ygyno.2006.06.013","article-title":"Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study","volume":"102","author":"Bell","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdq244_bb0220","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","article-title":"Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1093\/annonc\/mdq244_bb0225","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1093\/annonc\/mdq244_bb0230","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a gynecologic oncology group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0235","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ygyno.2007.02.030","article-title":"The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review","volume":"105","author":"Vernooij","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq244_bb0245","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0250","first-page":"144","article-title":"Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer","volume":"13","author":"Piccart","year":"2003","journal-title":"Int J Gynecol Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0255","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0260","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1006\/gyno.1993.1081","article-title":"A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA)","volume":"49","author":"Bertelsen","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0265","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/0090-8258(92)90305-3","article-title":"Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma","volume":"45","author":"Hakes","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0270","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1023\/A:1008256431090","article-title":"A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study","volume":"8","author":"Lambert","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0275","first-page":"34","article-title":"Phase III randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in stage III ovarian cancer: a Gynecologic Oncology Group Study","volume":"354","author":"Armostrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq244_bb0280","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1525-1438.2006.00846.x","article-title":"A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer","volume":"17","author":"Hess","year":"2007","journal-title":"Int J Gyn Cancer"},{"key":"10.1093\/annonc\/mdq244_bb0285","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0290","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0295","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2002.20.5.1232","article-title":"Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens","volume":"20","author":"Cant\u00f9","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0300","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/OVAR2.2 trial","volume":"361","author":"The ICON and AGO Collaborators","year":"2003","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq244_bb0305","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an Intergroup trial of the AGO-OVAR, the NCIC CTG, and EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0310","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/jco.2009.27.15_suppl.lba5509","article-title":"A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG)","volume":"27","author":"Pujade-Lauraine","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0315","series-title":"Intestinal obstruction in advanced ovarian cancerClinical Management of Ovarian Cancer","first-page":"165","author":"Ledermann","year":"2001"},{"key":"10.1093\/annonc\/mdq244_bb0320","doi-asserted-by":"crossref","first-page":"18s","DOI":"10.1200\/jco.2009.27.15_suppl.1","article-title":"A randomized trial in ovarian cancer of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05\/EORTC 55955 trials)","volume":"27","author":"Rustin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq244_bb0325","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2008.08.027","article-title":"The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project","volume":"112","author":"Fulham","year":"2009","journal-title":"Gynecol Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419396607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419396607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/suppl_5\/v23\/485348\/mdq244.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T18:15:11Z","timestamp":1635790511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419396607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":64,"alternative-id":["S0923753419396607"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq244","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}